Adjuvant Pembrolizumab in Resected Stage III Melanoma Reply

被引：0
|
作者：
Eggermont, Alexander M. M. [1 ]
Robert, Caroline [1 ]
Suciu, Stefan [2 ]
机构：
[1] Gustave Roussy Canc Campus Grand Paris, Villejuif, France
[2] European Org Res & Treatment Canc Headquarters, Brussels, Belgium
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 379卷 / 06期
关键词：
HIGH-RISK;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：593 / 595
页数：4
相关论文
共 50 条
  • [21] Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients
    Crookes, Thomas R.
    Scolyer, Richard A.
    Lo, Serigne
    Drummond, Martin
    Spillane, Andrew J.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (05) : 1378 - 1385
  • [22] Sequencing of Immunotherapy and Outcomes in Operable Clinical Stage III Melanoma: A National Cohort Study
    Dheer, Anushka
    Tortorello, Gabriella N.
    Shafique, Neha
    Farooq, Mohammad S.
    Mitchell, Tara C.
    Xu, Xiaowei
    Miura, John T.
    Karakousis, Giorgos C.
    JOURNAL OF SURGICAL ONCOLOGY, 2024, : 365 - 370
  • [23] Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
    Choueiri, T. K.
    Tomczak, P.
    Park, S. H.
    Venugopal, B.
    Ferguson, T.
    Chang, Y. -H.
    Hajek, J.
    Symeonides, S. N.
    Lee, J. L.
    Sarwar, N.
    Thiery-Vuillemin, A.
    Gross-Goupil, M.
    Mahave, M.
    Haas, N. B.
    Sawrycki, P.
    Gurney, H.
    Chevreau, C.
    Melichar, B.
    Kopyltsov, E.
    Alva, A.
    Burke, J. M.
    Doshi, G.
    Topart, D.
    Oudard, S.
    Hammers, H.
    Kitamura, H.
    Bedke, J.
    Perini, R. F.
    Zhang, P.
    Imai, K.
    Willemann-Rogerio, J.
    Quinn, D. I.
    Powles, T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08) : 683 - 694
  • [24] Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
    Choueiri, T. K.
    Tomczak, P.
    Park, S. H.
    Venugopal, B.
    Ferguson, T.
    Symeonides, S. N.
    Hajek, J.
    Chang, Y-H
    Lee, J-L
    Sarwar, N.
    Haas, N. B.
    Gurney, H.
    Sawrycki, P.
    Mahave, M.
    Gross-Goupil, M.
    Zhang, T.
    Burke, J. M.
    Doshi, G.
    Melichar, B.
    Kopyltsov, E.
    Alva, A.
    Oudard, S.
    Topart, D.
    Hammers, H.
    Kitamura, H.
    McDermott, D. F.
    Silva, A.
    Winquist, E.
    Cornell, J.
    Elfiky, A.
    Burgents, J. E.
    Perini, R. F.
    Powles, T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (15) : 1359 - 1371
  • [25] Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
    Dent, Rebecca
    Cortes, Javier
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Bergh, Jonas
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Haiderali, Amin
    Jia, Liyi
    Nguyen, Allison Martin
    Pan, Wilbur
    O'Shaughnessy, Joyce
    Schmid, Peter
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (10): : 1654 - 1663
  • [26] The brim of uncertainty in adjuvant treatment of melanoma
    Warner, Allison Betof
    Postow, Michael A.
    LANCET ONCOLOGY, 2018, 19 (04) : 436 - 437
  • [27] Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma
    Ponto, Jay
    Bell, R. Bryan
    ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA, 2022, 34 (02) : 315 - 324
  • [28] The new era of adjuvant therapies for melanoma
    Eggermont, Alexander M. M.
    Robert, Caroline
    Ribas, Antoni
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (09) : 535 - 536
  • [29] Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients
    Chen, Yong
    Yang, Yun
    Wang, Chunmeng
    Shi, Yingqiang
    JOURNAL OF SURGICAL ONCOLOGY, 2012, 106 (02) : 162 - 168
  • [30] Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?
    Tannock, Ian F.
    Goldstein, Daniel A.
    Ofer, Jonathan
    Gyawali, Bishal
    Meirson, Tomer
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2713 - +
12345